Dr Helen Fletcher BSc PhD
- Helen Fletcher's Contacts
- Keppel Street
- WC1E 7HT
- T: +44 (0) 20 7927 2666
- Follow me
I gained a PhD in Medical Microbiology from the University of Leeds and became interested in tuberculosis (TB) in 1999 during my first postdoctoral position at University College London. In 2002 I moved to the Jenner Institute at the University of Oxford as an immunologist for the first-in-man trial of a new TB vaccine, MVA85A. After 10 years at the Jenner Institute I moved to the London School of Hygiene & Tropical Medicine to establish my group, based in the Immunology and Infection Department, which focuses on immune correlates and the host response to TB vaccination. In 2015 I became Director of the TB Centre: http://tb.lshtm.ac.uk/ at the London School of Hygiene & Tropical Medicine and in 2016 I became co-chair of the T-cell Immunology working group for the Collaboration for TB Vaccine Discovery (CTVD) at the Bill & Melinda Gates Foundation.
I am co-organizer of the Vaccine Immunology MSc module with Eleanor Riley and I am a tutor on the Distance Learning programme
My interests are in vaccine development for TB and identification of immune mechanisms important for protection from TB
- Disease control
- Global Health
- Innate immunity
- T-cell immunology
Disease and Health Conditions
- Infectious disease
- Sub-Saharan Africa (all income levels)
- Gambia, The
- South Africa
- BCG Vaccination
- Cellular Immunology
- Malaria Centre
- Microarray Technology
- Next Generation Sequencing
- TB Centre
T-cell activation is an immune correlate of risk in BCG vaccinated infants.
Fletcher, H.A. ; Snowden, M.A. ; Landry, B. ; Rida, W. ; Satti, I. ; Harris, S.A. ; Matsumiya, M. ; Tanner, R. ; O'Shea, M.K. ; Dheenadhayalan, V. ; Bogardus, L. ; Stockdale, L. ; Marsay, L. ; Chomka, A. ; Harrington-Kandt, R. ; Manjaly-Thomas, Z.R. ; Naranbhai, V. ; Stylianou, E. ; Darboe, F. ; Penn-Nicholson, A. ; Nemes, E. ; Hatheril, M. ; Hussey, G. ; Mahomed, H. ; Tameris, M. ; McClain, J.B. ; Evans, T.G. ; Hanekom, W.A. ; Scriba, T.J. ; McShane, H. ;
Nat Commun, 2016; 7:11290
Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study.
Fletcher, H.A. ; Filali-Mouhim, A. ; Nemes, E. ; Hawkridge, A. ; Keyser, A. ; Njikan, S. ; Hatherill, M. ; Scriba, T.J. ; Abel, B. ; Kagina, B.M. ; Veldsman, A. ; Agudelo, N.M. ; Kaplan, G. ; Hussey, G.D. ; Sekaly, R.P. ; Hanekom, W.A. ; BCG study team, . ;
BMC Med, 2016; 14(1):76
Human biomarkers: can they help us to develop a new tuberculosis vaccine?
Fletcher, H.A. ; Dockrell, H.M. ;
Future Microbiol, 2016;
Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
Dunachie, S. ; Berthoud, T. ; Hill, A.V. ; Fletcher, H.A. ;
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes.
Naranbhai, V. ; Fletcher, H.A. ; Tanner, R. ; O'Shea, M.K. ; McShane, H. ; Fairfax, B.P. ; Knight, J.C. ; Hill, A.V. ;
EBioMedicine, 2015; 2(11):1619-1626
Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.
Matsumiya, M. ; Satti, I. ; Chomka, A. ; Harris, S.A. ; Stockdale, L. ; Meyer, J. ; Fletcher, H.A. ; McShane, H. ;
J Infect Dis, 2014;
Blood monocyte-lymphocyte ratios identify adults at risk of incident tuberculosis amongst patients initiating antiretroviral therapy.
Naranbhai, V.; Hill, A.V.; Abdool Karim, S.S.; Naidoo, K.; Abdool Karim, Q.; Warimwe, G.M.; McShane, H.; Fletcher, H.;
J Infect Dis, 2013;
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
McShane, H. ; Pathan, A.A. ; Sander, C.R. ; Keating, S.M. ; Gilbert, S.C. ; Huygen, K. ; Fletcher, H.A. ; Hill, A.V. ;
Nat Med, 2004; 10(11):1240-4
- → View all Dr Helen Fletcher 's publications